Risk factors and outcomes of creatine kinase elevation in chronic hepatitis B patients
10.16718/j.1009-7708.2017.02.005
- VernacularTitle:慢性乙型肝炎合并肌酸激酶升高相关因素与转归分析
- Author:
Wei LI
;
Qing WANG
;
Zhaohui WANG
;
Xiaoning ZHANG
- Keywords:
telbivudine;
creatine kinase;
chronic hepatitis B
- From:
Chinese Journal of Infection and Chemotherapy
2017;17(2):144-147
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the risk factors of creatine kinase (CK) elevation in chronic hepatitis B (CHB) patients and treatment outcomes for better management of such patients. Methods The CHB patients complicated with CK elevation who were treated during the period from June 2013 to June 2015 were reviewed retrospectively with their clinical data. CK elevation was examined in terms of antiretroviral regimens, and glycyrrhizin therapies. The clinical outcome was evaluated in terms of grade 3/4 CK elevation. Results A total of 364 CHB patients with CK elevation were included in this analysis. CK elevation was primarily associated with telbivudine monotherapy and combination therapy, followed by entecavir treatment. Grade 3/4 CK elevation was identified in 30 patients, which was mainly associated with telbivudine monotherapy and combination therapy. Good outcome was observed in most of these?patients?(76.7?%,?23/30).?Myopathy?was?confirmed?in?one?patient?by?muscle?biopsy.?Glycyrrhizin?was?not?associated?significantly?with CK elevation in CHB patients. Conclusions Creatine kinase elevation usually occurs in the CHB patients receiving telbivudine-containing therapies. CHB patients should be monitored for CK level during antiviral therapy. Concomitant glycyrrhizin treatment is not associated with CK elevation.
